common.study.topics.clinical

Postoperative Pain Management Study

common.study.values.description

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Exparel 266 MG Per 20 ML Injection

patients receive Exparel in bilateral TAP blocks for open abdomen surgery

participant.views.study.view.additional

participant.views.study.view.scientific-title

The Use of Exparel (Liposomal Bupivacaine) for Bilateral TAP (Transversus Abdominis Plane) Blocks in Open Abdomen Surgery for Postoperative Pain Control

common.study.values.clinical-trial-id

NCT03878888

participant.views.study.view.id

b2krWd